Mannin GmbH Implements CDD Vault Informatics Platform to Facilitate Data Management and Collaboration

]

LEIPZIG, Germany and SAN FRANCISCO, Nov. 24, 2021 /PRNewswire/ – Mannin GmbH, a biotechnology company specializing in the research and development for new vascular therapeutics, announced today that it has implemented CDD Vault in its Leipzig laboratories. CDD Vault, a hosted chemistry and biology research data management platform developed by Collaborative Drug Discovery, Inc. (CDD), will be used to manage all the company’s research data and collaborative projects across geographies.

Mannin has an established pipeline in eye diseases with a first-in-class drug for Primary Open Angle Glaucoma. It also has a new drug candidate designed to restore the normal flow of fluid in the eye and reduce intra-ocular eye pressure (IOP), one of the main causes of Glaucoma. Using the same principles, Mannin is developing novel therapeutics to treat a spectrum of vascular diseases including Cystic Kidney Disease, Paediatric Glaucoma, and inflammation.

CDD Vault is a hosted platform designed to manage drug discovery data including small molecules and biologics, as well as all the related experimental and contextual information. The platform incorporates fully integrated capabilities for Activity & Registration, Inventory, Visualization and a flexible Electronic Lab Notebook. It also includes a documented RESTful API that enables organizations to integrate CDD Vault with other software tools.

“I am very happy with the implementation of CDD Vault at Mannin. I highly value CDD Vault as a tool that offers not only a solution for a digital chemistry lab notebook, but also a database that combines chemical and biological data in a very powerful way,” said Dr. Andreas Schoop, Head of Medicinal Chemistry at Mannin. “This is especially important since we just opened our new labs for Medicinal Chemistry in Leipzig while most of the biology is performed by our parent company in Toronto, Canada or by external CROs. CDD Vault will help us share data and collaborate more effectively.”

“We are delighted that researchers at Mannin have chosen CDD Vault because their new therapeutics have the potential to change the lives of millions of people around the globe,” said Dr. Mariana Vaschetto, Head of EMEA Operations at CDD, “Pharma, biotechs and academics across Europe are increasingly adopting CDD Vault as their main research data management platform, and we are privileged to support them.”

ABOUT MANNIN GMBH

Mannin GmbH is a biotech company with research laboratories in the BioCity in Leipzig. Mannin´s development activities are focused on treatments of vascular diseases by targeting the Angiopoietin-Tie2 signaling pathway. Mannin is developing medications based on small molecules and biologics as well as companion diagnostics (e.g. to detect Glaucoma). Additionally, Mannin is scouting for and pursuing new innovations and development opportunities.

ABOUT COLLABORATIVE DRUG DISCOVERY, INC.

CDD’s (www.collaborativedrug.com) flagship product, “CDD Vault®”, is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

Contact:

Dr. Mariana Vaschetto

[email protected]

SOURCE Collaborative Drug Discovery

Altus Capital Partners-Backed MGC Diagnostics Corporation Acquires Lemon Medical, GmbH

]

SAINT PAUL, Minn.–(BUSINESS WIRE)–MGC Diagnostics Corporation (“MGC”), a global medical technology company dedicated to cardiorespiratory health solutions, and a portfolio company of Altus Capital Partners, Inc. (“Altus”), announced today the acquisition of Lemon Medical, GmbH. Lemon is a medical technology company, headquartered in Hammelburg, Germany. Financial terms of the transaction were not disclosed.

Lemon Medical, a German Limited Liability Company, founded in 2009, specializes in the design, development, production, and distribution of single-patient use disposables. These include viral and bacterial filters designed to protect patients, medical personnel, and diagnostic instruments against cross contamination during cardiorespiratory function testing. The usage of these protective products is experiencing significant growth because of the COVID pandemic and are now globally required patient safety components. In addition to the disposable products, Lemon develops, manufactures, and markets non-invasive diagnostic systems for detecting, classifying, and managing cardiorespiratory disease.

“MGC Diagnostics is excited to further strengthen its in-house manufacturing capabilities, product offering, and European presence through this acquisition of Lemon,” said Greg Greenberg, Co-Founder and Senior Partner of Altus Capital Partners. “We are thrilled about the opportunities this partnership will provide.”

“Following an exhaustive evaluation of the cardiorespiratory disposable filter market, MGC Diagnostics identified Lemon Medical, and its founder, Alfred Albert, as the ideal partner,” said Todd Austin, Chief Executive Officer of MGC. “This is another strategic acquisition for MGC Diagnostics, providing our own source of disposables as well as a significant footprint in the German market, one of the top cardiorespiratory scientific communities in the world.”

About MGC Diagnostics

Founded in 1977 and headquartered in Saint Paul, Minnesota, MGC Diagnostics Corporation, develops, manufactures, and markets non-invasive diagnostic systems for detecting, classifying, and managing cardiorespiratory disease. This singular focus guides its strategy and defines its commitment to customers, employees. and the cardiorespiratory industry. Its experience provides unmatched insight for solving today’s challenges and anticipating tomorrow’s opportunities. Please visit mgcdiagnostics.com for more information.

About Altus Capital Partners

Altus Capital Partners is a private equity firm that makes control investments in middle market manufacturing businesses that employ technology and automation. We believe that our exclusive focus on manufacturing provides us with a unique understanding of the opportunities and challenges faced by companies in the sector. We utilize a patient, thoughtful investment approach and partner with the management teams of our operating companies to achieve growth. Please visit altuscapitalpartners.com for more information.

About Lemon Medical, Inc.

Lemon Medical, a German Limited Liability Company, founded in 2009 by serial entrepreneur Alfred Albert, is headquartered in Hammelburg, Germany. Lemon Medical designs, develops, and distributes single patient use disposable bacterial and viral filters used in a variety of cardiorespiratory medical products. Please visit Lemon Medical for more information.

Vistex Forays into Big Data, Announces Acquisition of Webdata Solutions GmbH

]

HOFFMAN ESTATES, Ill, Nov. 22, 2021 /PRNewswire/ – Vistex Inc., the global leader in pricing, trade, royalties and incentives management solutions, announces the acquisition of Webdata Solutions GmbH’s assets and team, a leading technology provider of online market data that facilitates better pricing and product decisions for global organizations.

The ever-evolving landscape of B2B, B2C and increasingly D2C (Direct-To-Consumer) requires businesses to incorporate both internal and external data, to better plan, execute and analyze the effectiveness of pricing and commercial models. Compounded with the rapid rise of ecommerce sales, companies need not only access to more information but the right information.

“We are delighted to welcome the highly talented team to Vistex, and to bring their intellectual property into our portfolio,” said Sanjay Shah, Vistex Founder and CEO. “We are excited to empower our customers with market insights that will drive informed and strategic decision making for their go-to-market programs.”

“For our customers, it’s not just enough to collect product and pricing data – it has to be collated with their commercial systems,” said Carina Röllig, Founder and Managing Partner. “What sets us apart is our ability to analyze millions of lines of data on a daily basis and to extract and integrate it into business operations. That has been the driving force of success for our customers.” Dr. Hanna Köpcke, Founder and CTO added, “As part of Vistex, we will rapidly enhance our portfolio with visual search and next gen technologies, while integrating ecommerce scenarios.”

Founded in 2012, Webdata Solutions GmbH has seen tremendous growth over the last decade and has an impressive roster of customers. The company has also been acknowledged as being a rising star within the German technology ecosystem. Vistex will inject further capital into this platform to accelerate value for its customer base.

Roland Keppler, CEO of ONLINEPRINTERS, a leading online print shop serving more than a million customers in Europe, added, “The insights, delivery and accuracy of data from this platform is second to none. As part of the Vistex offering, we look forward to realizing additional benefits derived from accelerated product enhancements.”

About Vistex:

Vistex solutions help businesses take control of their mission-critical processes. With a multitude of programs covering pricing, trade, royalties and incentives, it can be complicated to see where all the money is flowing, let alone how much difference it makes to the topline and the bottomline. With Vistex, business stakeholders can see the numbers, see what really works, and see what to do next – so they can make sure every dollar spent or earned is really driving growth, and not just additional costs. The world’s leading enterprises across a spectrum of industries rely on Vistex every day to propel their businesses. For more information, visit www.vistex.com.

For more information, press only:

Alex Dehnert, Vistex, Inc., 847.490.0420. [email protected]

Copyright: Vistex®, Go-to-Market Suite®, and other Vistex, inc. graphics, logos, and service names are trademarks, registered trademarks or trade dress of Vistex, Inc. In the United States and other countries. The information contained in these materials is only for use by the recipient. No part of this publication may be reproduced or transmitted in any form or for any purpose without the express written permission of Vistex, Inc. The information contained herein may be changed without prior notice. All rights reserved. © Copyright 2021 Vistex, Inc.

SOURCE Vistex, Inc.